Advertisement
Advertisement
U.S. Markets open in 7 hrs 6 mins
Advertisement
Advertisement
Advertisement
Advertisement

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7910+0.0200 (+2.59%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7710
Open0.8048
Bid0.7575 x 3000
Ask0.8200 x 1200
Day's Range0.7617 - 0.8460
52 Week Range0.7400 - 11.0000
Volume202,610
Avg. Volume404,743
Market Cap34.529M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-2.8620
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.86
  • Zacks

    AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

    Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

  • Benzinga

    Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study

    Avrobio Inc (NASDAQ: AVRO) announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in infantile-onset Pompe disease. Pompe disease is a lysosomal disorder caused by a mutation in the GAA gene. The lack of the enzyme encoded by GAA results in a toxic buildup of glycogen throughout the body and central nervous system. The results demonstrate that gene therapy using hematopoietic stem cells (HSC) significantly reduced the toxic accumulation of glycogen in a mouse

  • Business Wire

    AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    CAMBRIDGE, Mass., May 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the "Disease models and Clinical Applications: Musculo-skeletal Diseases" poster session at the American Society of Gene

Advertisement
Advertisement